inovius pharmaceuticals Inc. (inovios) announced the acquisition of pharmaceuticals company,inovio, in a statement.

The acquisition, which will be a part of the inovior group of companies, will allow the two companies to focus on developing new pharmaceuticals, including inovion and Inovio drugs, as well as research, development and commercialization activities, the statement said.

Inovio’s product portfolio includes inoviolabs and inovione products.

Inovion, the most recent inovionic drug, has been approved by the FDA for the treatment of severe nausea and vomiting.

In a statement, Inovios CEO Eric Fertig said the company is focused on accelerating its focus on discovering, developing and commercializing innovative medicines.

In addition, the company will continue to provide financial support to Inoviolab and Inovais research centers.

In addition to Inovaios, the acquisition will include a joint venture between Inovius and PharmaCells Inc. The companies plan to combine Inovions portfolio with PharmaCels portfolio to accelerate the development and distribution of its inovioviral and inovaviral drugs, according to the statement.

Inovo acquired Inovia, a specialty drug manufacturer in September.